CXCR2 (C-X-C chemokine receptor type 2) is a G protein-coupled receptor (GPCR) that binds chemokines such as CXCL1. CXCL2. CXCL5. CXCL7. and CXCL8 (IL-8). It plays a critical role in neutrophil recruitment, inflammation, and angiogenesis by mediating cell migration and activation. CXCR2 is expressed on immune cells (e.g., neutrophils, monocytes) and non-immune cells (e.g., endothelial cells, epithelial cells), and its dysregulation is linked to chronic inflammatory diseases (e.g., COPD, psoriasis), cancer progression, and autoimmune disorders.
CXCR2 antibodies are tools designed to target and modulate the receptor’s activity. They include antagonistic antibodies that block ligand binding or receptor signaling, inhibiting inflammatory responses or tumor growth, and agonistic antibodies used to study receptor activation. These antibodies are widely employed in research to explore CXCR2’s role in disease mechanisms, immune cell trafficking, and tissue repair. Therapeutically, CXCR2 antagonists are being investigated in clinical trials for conditions like asthma, cancer metastasis, and neutrophilic inflammation. However, challenges remain in balancing efficacy with potential side effects, as systemic inhibition may impair host defense. As a biomarker, CXCR2 expression levels are also studied to correlate with disease severity or treatment response.